Journal Management System
ScopeMed is an
Online Journal/Article Management system
that can enable all of the operations of
the editorial functions of a journal.
Home  |   Add your Journal  |   Features  |   Job Opportunities  |   Journal List
Author Login | Reviewer Login | Editor Login
Search  

International Journal of Medical Research & Health Sciences
Periodical of Sumathi Publications
Journal Home Page
ISSN: 2319-5886 (Online)
Language: [ English ]  
News / Announcements

  » Volume 3, Issue 2
      pp. 228-508
  » Volume 3, Issue 1
      pp. 1-227

 

Open Access

Review Article

IJMRHS. 2013; 2(2): 250-253


New drugs in the pipeline: A review

Dr Vivek Lal.

A B S T R A C T 

Abstract
Pharmacology is a rapidly advancing science. The essence of rational pharmacotherapeutics is to maximize the efficacy of a pharmaceutical Interventional product for a specific indication, with a simultaneous minimization of its adverse effects. With this primary objective in mind, research and development activities of pharmaceutical companies and other healthcare research organizations focus on the development and screening of new chemical entities (NCE). Once a definite pharmacological action of the NCE has been discovered, which is expected to be of satisfactory therapeutic value, the molecule is taken for a thorough pre-clinical animal testing in order to determine its feasibility for human clinical trials. Positive outcomes of the animal studies facilitate the submission of an Investigational New Drug (IND) application with the requisite drug regulatory authority of that particular country. The molecule then undergoes Phase I-III Clinical Trials before it can get a marketing approval. Alternatively, an existing molecule can be modified as per the structure activity relationships to enhance its efficacy or safety. There are numerous examples of structural modifications yielding much better pharmacokinetic and or pharmacodynamic profiles. Introduction of new and better drugs ensure a continuous improvement in the management of patients with all types of ailments. A post marketing surveillance facilitates evidence based medicine, so also in the detection, assessment and analysis of adverse events which constitutes the discipline of Pharmacovigilance.

Key words: Abiraterone, Avanafil, Canagliflozin, Daclatasvir, Linaclotide, Pasireotide, Tafluprost


ARTICLE TOOLS
Abstract
PDF Fulltext
Email this Article
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Dr Vivek Lal
on IndexScholar Fulltext
on Google
on Google Scholar
Article Statistics
 Viewed: 463
Downloaded: 141
(Last 7 Days: 7)
Cited: 0
Emailed: 0

How to Cite this Article
Pubmed Style

Lal DV. New drugs in the pipeline: A review. IJMRHS. 2013; 2(2): 250-253.



Web Style

Lal DV. New drugs in the pipeline: A review. www.scopemed.org/?mno=36772 [Access: April 18, 2014].



AMA (American Medical Association) Style

Lal DV. New drugs in the pipeline: A review. IJMRHS. 2013; 2(2): 250-253.



Vancouver/ICMJE Style

Lal DV. New drugs in the pipeline: A review. IJMRHS. (2013), [cited April 18, 2014]; 2(2): 250-253.



Harvard Style

Lal, D. V. (2013) New drugs in the pipeline: A review. IJMRHS, 2 (2), 250-253.



Turabian Style

Lal, Dr Vivek. 2013. New drugs in the pipeline: A review. International Journal of Medical Research & Health Sciences, 2 (2), 250-253.



Chicago Style

Lal, Dr Vivek. "New drugs in the pipeline: A review." International Journal of Medical Research & Health Sciences 2 (2013), 250-253.



MLA (The Modern Language Association) Style

Lal, Dr Vivek. "New drugs in the pipeline: A review." International Journal of Medical Research & Health Sciences 2.2 (2013), 250-253. Print.



APA (American Psychological Association) Style

Lal, D. V. (2013) New drugs in the pipeline: A review. International Journal of Medical Research & Health Sciences, 2 (2), 250-253.







Total Download: 22.261
(for International Journal of Medical Research & Health Sciences)
Total Submission during last 24 hours: 169


» For Authors




Become Reviewer


» Login Area




Follow ScopeMed on Twitter

ScopeMed Home | About ScopeMed | Contact Us | Terms & Conditions | Privacy Policy
The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of SAGEYA Publishing for Scientific Publications. Copyright © ScopeMed® International Medical Journal Management and Indexing System.